The text discusses adjuvant treatments for stage II colorectal cancer, recommending no adjuvant chemotherapy for stage II MSS cancers without poor prognostic factors, and no adjuvant chemotherapy for stage II MSI cancers. It also suggests testing for DPD deficiency and adjusting chemotherapy doses accordingly. Chemotherapy may be considered for patients without comorbidities and in good health, with specific criteria outlined.